Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

LPPDS

Financiado

A portable peritoneal dialysis system for home use that monitors for infection

End Stage Kidney Disease (ESKD) or End Stage Renal Disease (ESRD), the fifth and last stage of Chronic Kidney Disease (CKD), is recognised as a major public health problem. It occurs where kidneys are no longer capable of sufficie... ver más

30/11/2018

LIBERDI

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

LIBERDI LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-11-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 6 años

0% 70% 100%

2 Participantes

LIBERDI

50.00K€ | Lider

SARRIMAD

570.19K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 3 meses Fecha Inicio: 2018-08-02
Fecha Fin: 2018-11-30

Líder del proyecto

LIBERDI LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Descripción del proyecto End Stage Kidney Disease (ESKD) or End Stage Renal Disease (ESRD), the fifth and last stage of Chronic Kidney Disease (CKD), is recognised as a major public health problem. It occurs where kidneys are no longer capable of sufficiently filtering waste products from the blood. With kidney function at less than 10 %, a kidney transplant or an external means of filtering is needed. The latter consists of either Haemodialysis (HD) or Peritoneal Dialysis (PD). Globally, we are seeing an increasing prevalence in ESRD. This is caused by an aging population in the west, socio-economic factors, increasing hypertension, and growing diabetes and obesity epidemics. The technical complexity of market offerings can inhibit many patients from choosing PD. HD takes an average of 4 hours per treatment session and occurs 3 times a week while PD occurs 4 times a day with each exchange requiring 40 minutes on average. Most dialysis occurs in specific dialysis centres and hospitals, adding further time for travel. Non-compliance with treatment schedules are a particular issue with PD. This makes it difficult for doctors to calculate correct treatment plans as patients may not share this information with their doctor. Non-compliance can be as high as 53%, decreasing efficacy of the treatment leading to poorer health overall and speeds up rate of decline. liberDi revolutionises traditional Peritoneal Dialysis with LPPDS, a smart, real-time, patient-monitoring, truly portable device. It’s lightweight, easy to set up and allows patients carry out their dialysis at home, at work or while travelling. LPPDS has UX at the very core of its design to ensure ease of use: patent pending smart automation, catheters and sterile connectors. The system consists of a patent-pending disposable that holds a smart peristaltic pump designed to improve adherence to protocol, and reduce human errors, while saving time via fluid flow rate and management.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores